Improved oral glucose tolerance following antiserotonin treatment in patients with chemical diabetes.
The effects of short-term treatment with either placebo or two serotonin antagonists, cyproheptadine and metergoline, on oral glucose tolerance and insulin secretion have been evaluated in normal subjects and in patients with chemical diabetes. Placebo treatment was not associated with any significant change in the parameters examined. Glucose tolerance in chemical diabetics was significantly improved both after cyproheptadine and metergoline; fasting plasma glucose was also reduced by metergoline. Treatment with the latter drug was also associated with a significant decrease in incremental glucose area in healthy subjects, which was not affected by cyproheptadine. Basal and glucose-stimulated insulin secretion were not affected by either drug in any subjects. Cyproheptadine and metergoline improve glucose metabolism in chemical diabetes probably by reducing insulin resistance. This may depend either on decreased secretion of counter-regulatory hormones or on a direct pharmacological action of the drugs on glucose utilization, possibly mediated by their common antiserotoninergic properties.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003533:Cyproheptadine / Q000627:therapeutic use; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008711:Metergoline / Q000627:therapeutic use; D008875:Middle Aged; D011236:Prediabetic State / Q000188:drug therapy* / Q000378:metabolism; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013997:Time Factors
D001786:Blood Glucose; D007328:Insulin; D012702:Serotonin Antagonists; D008711:Metergoline; D003533:Cyproheptadine